iOganovR.G., TimofeevaT.N., Koltunov I.E., Konstantinov V.V., BalanovaYu.A., Kapustina A.V., Lelchuk I.N.,
Shalnova S.A., Deev A.D. Epidemiology of arterial hypertension in Russia. Federalmonitoringresultsfor2003-2010
// Cardiovascular Therapy and Prevention, 2011.-N 1.-С.9-13
iiABC Of Hypertension / edited by D. Gareth Beevers, Gregory H. Lip and Eoin O'Brien. 5th ed. Malden, Mass.:
BMJ Books, 2007, p.88
410
Indian Journal of Basic and Applied Medical Research; December 2014: Vol.-4, Issue- 1, P. 400-414
401
www.ijbamr.com P ISSN: 2250-284X , E ISSN : 2250-2858
iiiOganovR.G., TimofeevaT.N., Koltunov I.E., Konstantinov V.V., BalanovaYu.A., Kapustina A.V., Lelchuk I.N.,
Shalnova S.A., Deev A.D. Epidemiology of arterial hypertension in Russia. Federalmonitoringresultsfor 2003-2010
// Cardiovascular Therapy and Prevention, 2011.-N 1.-С.9-13
ivABC Of Hypertension / edited by D. Gareth Beevers, Gregory H. Lip and Eoin O'Brien. 5th ed. Malden,
Mass.:BMJ Books, 2007, p.88
vStamler J, Wentworth D, Neaton D. Prevalence and prognostic significance of hypercholesterolemia in men with
hypertension: Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am J
Med. 1986;80:33–9.
viAlexander, W.R., Hypertension and the Pathogenesis of Atherosclerosis.Hypertension. 1995; 25: 155-161
viiO’Donnell VB. Free radicals and lipid signaling in endothelial cells. Antiox Redox Signal.2003;5:195–203.
viiiWolfrum S, Jensen KS, Liao JK.Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003;
23:729–36.
ixNakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of
hypertension? ProcNatlAcadSci U S A. 1991;88:10045-10048.
xiСhobanian AV. Clinical practice.Isolated systolic hypertension in the elderly. N Engl J Med 2007; 357:789-96.
xiiNofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and arteriosclerosis: beyond
reverse cholesterol transport. Atherosclerosis 2002; 161:1-16.
xiiiCardillo C, Kilcoyne CM, Cannon RO, Panza JA. Increased activity of endogenous endothelin in patients with
hypercholesterolemia. J Am CollCardiol 2000;36:1483-8.
xivWorking Group on Management of Patients with Hypertension and High Blood Cholesterol. National education
programs working group report on the management of patients with hypertension and high blood cholesterol. Ann
Intern Med 1991;114:224.
xvWierzbickiAS. Lipid lowering: Another method of reducing blood pressure? J Hum Hypertens 2002;16:753-60.
xviSinha R, Dufour S, Petersen KF, et al. Assessment of skeletal muscle triglyceride content by (1)H nuclear
magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat,
and central adiposity. Diabetes 2002;51(4):1022–7.
xviiJohannsen DL, Ravussin E. Can increased muscle ROS scavenging keep older animals young and metabolically
fit? Cell Metab 2010; 12(6):557–8.
xviiiPreedy VR, Adachi J, Asano M, et al. Free radicals in alcoholic myopathy: indices of damage and preventive
studies. Free RadicBiol Med 2002; 32(8):683–7.
xixVictor VM, Rocha M, Herance R, et al. Oxidative stress and mitochondrial dysfunction in type 2 diabetes. Curr
Pharm Des 2011; 17(36):3947–58.
xxMorgado M., Rolo S., Macedo A.F., Castelo-Bran-co M. // J. Cardiovasc. Dis. Res. – 2011. – Vol. 2(1). – P. 44–49
xxiBorghi C, Prandin G, Costa V, Bacchelli S, Degli D, Ambrosioni E. Use of statins and blood pressure control in
treated hypertensive patients with hypercholesterolemia. J Cardio vasc Pharmacol 2000;35:549-55.
411
Indian Journal of Basic and Applied Medical Research; December 2014: Vol.-4, Issue- 1, P. 400-414
402
www.ijbamr.com P ISSN: 2250-284X , E ISSN : 2250-2858
xxiiBorghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A. Association between different lipid-lowering treatment
strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004;148:285-92.
xxiiiSorrentino S, Landmesser U. Nonlipid-lowering effects of statins. Curr Treat Options Cardiovasc Med 2005;7(6)
:459–66.
xxiv Zhou Q, Liao JK. Pleiotropic effects of statins. - Basic research and clinical perspectives. Circ J 2010;74
(5):818–26.
xxvWang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results.
Trends Mol Med 2008;14(1):37–44.
xxviColhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin
in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicen trerandomised placebocontrolled
trial. Lancet 2004; 364(9435):685–96.
xxviiKoh KK, Quon MJ, Rosenson RS, et al. Vascular and metabolic effects of treatment of combined hyperlipidemia
: focus on statins and fibrates. Int J Cardiol 2008;124(2):149–59.
xxviiiRawlings R, Nohria A, Liu PY, et al. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg)
on rho kinase activity in caucasian men with a previous atherosclerotic event. Am J Cardiol 2009;103(4):437–41.
xxixLiu PY, Liu YW, Lin LJ, et al. Evidence for statin pleiotropy in humans: differential effects of statins and
ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation.
Circulation 2009;119(1):131–8.
xxxKoh KK, Quon MJ, Rosenson RS, et al. Vascular and metabolic effects of treatment of combined hyperlipidemia:
focus on statins and fibrates. Int J Cardiol 2008;124(2):149–59.
xxxiGabay C, KushnerI. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;
340(6): 448–54.
xxxiiWang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular
smooth muscle. Circulation 2003; 107(13):1783–90.
xxxiiiKleemann R, Verschuren L, de Rooij BJ, et al. Evidence for anti-inflammatory activity of statins and PPA
Ralpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro.
Blood 2004;103(11): 4188–94.
xxxivFerrario CM, Richmond RS, Smith R, et al. Reninangiotensin system as a therapeutic target in managing
atherosclerosis. Am J Ther 2004;11(1): 44–53.
xxxvESH-ESC Guidelines Committee.2013 guidelines for the management of arterial hypertension. Journal of
Hypertension 2013, 31:1281–1357
xxxviYusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA 2001; 286 (15):
1882–5.
xxxviiBarzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic
adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive
412
Indian Journal of Basic and Applied Medical Research; December 2014: Vol.-4, Issue- 1, P. 400-414
403
www.ijbamr.com P ISSN: 2250-284X , E ISSN : 2250-2858
and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006;166(20): 2191–
201.
xxxviii Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;
355(15): 1551–62.
xxxixMcMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular
events. N Engl J Med 2010; 362(16):1477–90.
xlVan Linthout S, Spillmann F, Lorenz M, et al. Vascular-protective effects of high-density lipoprotein include the
downregulation of the angiotensin II type 1 receptor. Hypertension 2009;53(4):682–7.
xliOlsen MH, Wachtell K, Beevers G, et al. Effects of losartan compared with atenolol on lipids in patients with
hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension
study. J Hypertens 2009;27(3): 567–74.
xliiNishida Y, Takahashi Y, Nakayama T, et al. Effect of candesartan monotherapy on lipid metabolism in patients
with hypertension: a retrospective longitudinal survey using data from electronic medical records. Cardio vasc
Diabetol 2010;9:38.
xliiiAsymmetric dimethylarginine causes cardiac dysfunction in humans and is actively metabolized by dimethyl
arginine dimethyl amino hydrolase / [V. Acham, V. Broadhead, G. Malaki et al.] // Arterioscler. Thromb.Vasc.Biol.
— 2003. — 23. — Р. 1455-1459.
xlivRidker P.M., Danielson E., Rifai N., Glynn R.J. Valsar tan, blood pressure reduction and Creactive protein: pri
mary report of the ValMARC trial // J. Hypertens.— 2006.— Vol. 48.— P. 73—79.
xlvPlisiukA.G., KulevB.D, AzizovaO.A., OvchinnikovA.G., FofanovaT.V., AgeevF.T.//
EffectsofcombinedLisinoprilandSimvastatintherapyonelasticpropertiesoflargearteriesinpatientswith arterial
hypertension andmoderatedyslipidemia//Pharmateka2009;№4; p. 65-70.
xlviStrazzullo P., Kerry S.M., Barbato A. et al. // Hypertension. – 2007. – Vol. 49(4). – P. 792–798.
xlviiStrazzullo P., Kerry S.M., Barbato A., et al: Do statins reduce blood pressure? A meta-analysis of randomized
controlled trials. Hypertension 2007; 49: 792-798
xlviiiBorghi C., Dormi A., Veronesi M., et al :Brisighella Heart Study Working Party Association between different
lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004; 148:
285-292
xlixSever P, et al. Potential synergy between lipidlowering and blood-pressure-lowering in the Anglo-Scandinavian
Cardiac Outcomes Trial. Eur\ Heart J 2006;27:2982–88.
lAthyros VG, et al. Effect of statins and ACE inhibitors alone in combination on clinicaloutcome in patients with
coronary heart disease.J Hum Hypertens 2004;11:781–88.
liRodriguez-Porcel M., Lerman L.O., Herrmann J., et al: Hypercholesterolemia and hypertension have synergistic
deleterious effects on coronary endothelial function. ArteriosclerThrombVascBiol 2003; 23: 885-891
liiNickenig G., Sachinidis A., Michaelsen F., et al: Upregulation of vascular angiotensin II receptor gene expression
by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95: 473-478
413
Indian Journal of Basic and Applied Medical Research; December 2014: Vol.-4, Issue- 1, P. 400-414
404
www.ijbamr.com P ISSN: 2250-284X , E ISSN : 2250-2858
liiiWang C.H., Li S.H., Weisel R.D., et al: C-reactive protein upregulates angiotensin type 1 receptors in vascular
smooth muscle. Circulation 2003; 107: 1783-1790
livKoh K.K., Ahn J.Y., Han S.H., et al: Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.
J Am CollCardiol 2003; 42: 905-910
lvFukai T., Siegfried M.R., Ushio-Fukai M., et al: Modulation of extracellular superoxide dismutase expression by
angiotensin II and hypertension. CircRes 1999; 85: 23-28
lviAronovD. M. Pleiotropiceffectsofstatins// RMJ. 2001. № 9. P. 2–7.
lvii LaufsU., LaFataV., PlutzkyJ., LiaoJ.K.
UpregulationofendothelialnitricoxidesynthasebyHMGCoAReductaseinhibitors // Circulation. - 1998. - Vol. 97, №2.
- P. 1129 - 1135.
lviiiVitaJ.A., YeungA.C., WinnifordM., etal. Effect of cholesterol-lowering therapy on coronary endothelial
vasomotor function in patients with coronary artery disease // Circulation. - 2000. - Vol. 102, №8. - P. 846 - 851.
lixDelles, C., et al., Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the
levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens, 2002.
15(7 Pt 1): p. 590-3.
lxPaiva, H., et al., Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase
inhibitors. J CardiovascPharmacol, 2003. 41(2): p. 219-22.
lxiAlberto Zanchetti; Gaetano Crepaldi; M. Gene Bond ., et al: Different Effects of Antihypertensive Regimens
Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of
Asymptomatic Carotid Atherosclerosis Principal Results of PHYLLIS—A Randomized Double-Blind Trial
Stroke. 2004;35:2807-2812
Thank you for copying data from http://www.arastirmax.com
